- Home
- FIVN vs CGON Comparison
FIVN vs CGON Comparison
Compare FIVN & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- CGON
- Stock Information
- Founded
- FIVN 2001
- CGON 2010
- Country
- FIVN United States
- CGON United States
- Employees
- FIVN N/A
- CGON N/A
- Industry
- FIVN EDP Services
- CGON
- Sector
- FIVN Technology
- CGON
- Exchange
- FIVN Nasdaq
- CGON NYSE
- Market Cap
- FIVN 2.0B
- CGON 2.1B
- IPO Year
- FIVN 2014
- CGON 2024
- Fundamental
- Price
- FIVN $27.71
- CGON $26.90
- Analyst Decision
- FIVN Buy
- CGON Strong Buy
- Analyst Count
- FIVN 21
- CGON 10
- Target Price
- FIVN $43.95
- CGON $64.44
- AVG Volume (30 Days)
- FIVN 2.2M
- CGON 868.1K
- Earning Date
- FIVN 08-07-2025
- CGON 08-07-2025
- Dividend Yield
- FIVN N/A
- CGON N/A
- EPS Growth
- FIVN N/A
- CGON N/A
- EPS
- FIVN N/A
- CGON N/A
- Revenue
- FIVN $1,074,633,000.00
- CGON $662,000.00
- Revenue This Year
- FIVN $11.81
- CGON N/A
- Revenue Next Year
- FIVN $9.79
- CGON $25,206.93
- P/E Ratio
- FIVN N/A
- CGON N/A
- Revenue Growth
- FIVN 14.44
- CGON 224.51
- 52 Week Low
- FIVN $21.04
- CGON $14.80
- 52 Week High
- FIVN $49.90
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- FIVN 54.70
- CGON 59.29
- Support Level
- FIVN $26.06
- CGON $25.51
- Resistance Level
- FIVN $27.47
- CGON $27.28
- Average True Range (ATR)
- FIVN 0.96
- CGON 1.01
- MACD
- FIVN -0.05
- CGON 0.02
- Stochastic Oscillator
- FIVN 84.95
- CGON 89.23
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.